Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: A single institution study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 1, 2011, Pages 38-42

  Tourkantonis, Ioannis ^a   Makrilia, Nektaria ^a   Ralli, Maria ^a   Alamara, Christina ^a   Nikolaidis, Ilias ^a   Tsimpoukis, Sotirios ^a   Charpidou, Andriani ^a   Kotanidou, Anastasia ^a   Syrigos, Kostas ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

docetaxel; gemcitabine; mesothelioma; second line chemotherapy

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; PEMETREXED; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HUMAN; LUNG DISEASE; LUNG FUNCTION; MALE; MALIGNANT PLEURA MESOTHELIOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PNEUMONIA; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79951670415     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181cae90e     Document Type: Article

References (39)

1. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666-672. (Pubitemid 29046253)
2. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleu-ral nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-65. (Pubitemid 29022249)
3. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonec-tomies. J Thorac Cardiovasc Surg. 2004;128:138-146. (Pubitemid 38881208)
4. Baldini EH. External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin. 2004;14:543-548. (Pubitemid 39314488)
5. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6:147-153. (Pubitemid 18040002)
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644. (Pubitemid 46606305)
7. Giaccone G, O'Brien ME, Byrne MJ, et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer. 2002;38(suppl 8):S19-S24. (Pubitemid 41127956)
8. Porta C, Zimatore M, Bobomi L, et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer. 2005;48:429-434. (Pubitemid 40693630)
9. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol. 2003;21:349-354. (Pubitemid 46606165)
10. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 2007;109:93-99. (Pubitemid 46120198)
11. Vogelzang NJ. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma? . J Clin Oncol. 1999;17:2626-2627. (Pubitemid 29368268)
12. Sørensen JB, Sundstrøm S, Perell K, et al. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol. 2007;2:147-152. (Pubitemid 47181344)
13. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008; 26:5139-5140.
14. Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol. 2003;21:2636-2644.
15. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma. Cancer. 2003; 97:2791-2797. (Pubitemid 36605147)
16. Mbidde EK, Smith IE, Harland SJ. Phase II trial of carboplatin in the treatment of patients with malignant pleural mesothelioma. Br J Cancer. 1986;54:215-216.
17. Vorobiof DA, Rapoport BL, Chasen MR, et al. Malignant pleural mesothe-lioma: a phase II trial with docetaxel. Ann Oncol. 2002;13:412-415. (Pubitemid 34705002)
18. Belani CP, Adak S, Aisner S, et al. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Clin Lung Cancer. 2004;6:43-47. (Pubitemid 39199285)
19. Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol. 2002;29:70-76. (Pubitemid 34163537)
20. van Meerbeeck JP, Baas P, Debruyne C, et al; European Organization for Research and Treatment of Cancer Lung cancer Cooperative Group. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer. 1999;85:2577-2582. (Pubitemid 29272743)
21. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17: 25-30. (Pubitemid 29022374)
22. Nowak AK, Byrne MJ, Williamson R, et al. Multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002; 87:491-496.
23. van Haarst JM, Baas P, Manegold CH, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. B J Cancer 2002;86:342-345. (Pubitemid 34187648)
24. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma. Cancer. 2003; 97:2791-2797. (Pubitemid 36605147)
25. Manegold C, Symanowski J, Gatzemeier U, et al. Second line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16:923-927. (Pubitemid 40903918)
26. Syrigos KN, Dannos I, Dionellis G, et al. Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. Anticancer Res. 2005;25:3489-3493. (Pubitemid 41105228)
27. Syrigos KN, Karapanagiotou E, Charpidou A, et al. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study. J Chemother. 2007;19:438-443. (Pubitemid 47236524)
28. Karapanagiotou EM, Charpidou A, Tzannou I, et al. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer. Med Oncol. 2008;25:303-308.
29. Georgoulias V, Androulakis N, Kotsakis A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008;59:57-63.
30. Syrigos KN, Konstantinou M, Sepsas E, et al. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Anticancer Res. 2007;27:2887-2892. (Pubitemid 47228016)
31. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23:2937-2945. (Pubitemid 46224112)
32. Kosmidis PA, Kalofonos HP, Christodoulou C, et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol. 2008;19:115-122.
33. Kosmas C, Tsavaris N, Syrigos K, et al. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol. 2007;59:51-59. (Pubitemid 44796102)
34. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer. 2004;91:482-488. (Pubitemid 39093567)
35. Kosmidis PA, Dimopoulos MA, Syrigos K, et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol. 2007;2:135-140. (Pubitemid 47181342)
36. Ralli M, Tourkantonis I, Makrilia N, et al. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res. 2009;29:3441-3444.
37. Janne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006; 1:506-512. (Pubitemid 47181396)
38. Serke M, Xanthopoulos A, Bauer T. Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/gemcitabine [abstract]. Ann Oncol 2006;17(suppl 9):231a.
39. Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555-1561. (Pubitemid 351441168)